Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of ss-31 25mg in China. Welcome to wholesale bulk high quality ss-31 25mg for sale here from our factory. Good service and reasonable price are available.
SS-31 also comes with a standard therapeutic dose specification of 25mg, namely SS-31 25mg. As a highly selective mitochondrial-targeted synthetic short tetrapeptide agent, SS-31 (also known as Elamipretide) has consistently demonstrated extensive, multi-faceted and significant biological protective activity across multiple chronic disease fields entirely thanks to its distinctive molecular structure and unique intracellular mechanism of action. It readily penetrates the intact blood-brain barrier to reach central nervous tissue, effectively regulate excessive pathological oxidative stress, permanently block abnormal mitochondrial permeability transition pore (mPTP) opening triggered by toxic stimuli.
Our products Form
SS-31 COA
Exhibits Protective Functions in Renal and Metabolic Diseases
This represents a multidimensional intervention effect centered on mitochondrial homeostasis. As a synthetic tetrapeptide targeting the inner mitochondrial membrane, it's protective role in renal and metabolic diseases focuses on key conditions such as diabetic nephropathy and metabolic disorder-related kidney injury.By remodeling mitochondrial function, regulating oxidative stress, and blocking pathological cascades, it achieves precise protection of renal tissue and optimization of metabolic status, offering an innovative mitochondria-targeted strategy for the intervention of such diseases,core research methods for validating the renal and metabolic protective effects of elamipretide.
To scientifically confirm the effects of it in mitigating diabetic nephropathy injury, inhibiting mitochondrial fission, inflammation, and fibrosis, and improving metabolic disorders and oxidative stress, a multi-level approach combining cellular experiments, animal models, molecular mechanism analysis, and clinical studies is required.The following outlines targeted core research methods and their validation logic:cellular-level validation: in vitro experiments precisely simulating pathological environments.Cellular experiments form the foundation for verifying the direct effects of the drug.
By constructing cell models related to renal and metabolic diseases, the impact of this on cell function, mitochondrial status, and pathological pathways can be directly observed.
Validation of Oxidative Stress Effects:Intracellular reactive oxygen species (ROS) levels are detected via flow cytometry (using DCFH-DA fluorescent probe staining). Colorimetric or fluorescent assays measure the activity of intracellular antioxidant enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GPx), as well as the content of oxidative stress markers like malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). This clarifies SS-31's regulatory effect on oxidative stress.
Detection of Mitochondrial Function and Dynamics: A mitochondrial membrane potential detection kit (JC-1 staining) is used with fluorescence microscopy or flow cytometry to observe changes in membrane potential and assess mitochondrial integrity. Immunofluorescence staining (combining MitoTracker probes to label mitochondria with target protein immunofluorescence) and confocal laser scanning microscopy observe mitochondrial morphology (e.g., fragmentation), quantifying mitochondrial length/width ratios. Western blotting detects the expression levels of mitochondrial fission proteins (DRP1, FIS1) and fusion proteins (Mfn1, Mfn2, OPA1), verifying it's regulation of mitochondrial dynamic balance.
Construction of High-Glucose-Induced Cell Models: Utilize key renal cells such as human renal tubular epithelial cells (HK-2) and glomerular mesangial cells (HMC). These cells are incubated in high-glucose medium (25-30 mmol/L glucose) to simulate the hyperglycemic pathological environment of diabetic nephropathy. Normal glucose control groups and mannitol osmotic pressure control groups are established concurrently to exclude osmotic pressure interference.
Animal Model Validation: In Vivo Experiments Simulating Disease Progression:Animal models replicate the overall pathological environment of the disease, verifying the protective effects of this drug at the organ level and its in vivo safety. This serves as a crucial bridge connecting cellular experiments and clinical research.
Construction of Diabetic Nephropathy Animal Models:Classic model animals are selected, including db/db mice (spontaneous type 2 diabetes model, naturally developing nephropathy) and STZ (streptozotocin)-induced rat/mouse models (chemically induced type 1 diabetes, progressing to nephropathy). Animals are fed for 8-12 weeks to establish stable diabetic nephropathy models (marked by elevated urine microalbumin/creatinine ratio and renal histopathological damage). Normal control groups, model control groups, and it intervention groups at different doses (subcutaneous/intraperitoneal injection, simulating clinical administration routes) are established.
Detection of Renal Tissue Histopathology:At the experimental endpoint, kidney tissues are collected, fixed in formaldehyde, embedded in paraffin, and sectioned for pathological analysis. Staining techniques include H&E (observing renal tubular structural disorder and interstitial edema), PAS (detecting glomerular mesangial matrix hyperplasia and basement membrane thickening), and Masson's trichrome (quantifying renal interstitial fibrosis area). Pathological image analysis systems are used for scoring, visually assessing the improvement effect of SS-31 25mg on renal tissue damage.
Detection of Mitochondrial Function and Morphology: The classic Clark oxygen electrode detection method quantitatively measures the activity of key mitochondrial respiratory chain complexes (I, III, IV) and total cellular ATP production capacity. High-resolution transmission electron microscopy (TEM) directly observes mitochondrial ultrastructure features (cristae integrity, fragmentation, swelling), accurately quantifying the proportion of morphologically abnormal mitochondria in each sample. This series of detection indexes fully verifies the reparative protective effect of elamipretide on renal mitochondrial structure and overall energy function.
Assessment of Metabolic Disorders and Systemic Effects:Model animals are regularly monitored for body weight, blood glucose, and glycated hemoglobin (HbA1c) levels to evaluate SS-31's regulation of glucose metabolism. Serum total cholesterol, triglycerides, and LDL-cholesterol levels are measured to verify improvement in lipid metabolism. Concurrently, renal function indicators such as serum urea nitrogen and creatinine are assessed to evaluate the drug's overall renal protective effect.
Detection of Inflammatory and Fibrotic Molecular Markers
Total protein and RNA are extracted from renal tissues. Western blot and RT-qPCR detect the expression of key molecules such as DRP1, Mfn2, TGF-β1, α-SMA, and NF-κB. Immunohistochemistry/immunofluorescence staining localizes the expression sites of target proteins within renal tissues (e.g., renal tubular epithelial cells, interstitial areas), clarifying the cellular targets of SS-31's action.
Translational Research Bridging Basic Research and Clinical Application
Clinical studies can further confirm the safety and efficacy of this in humans, providing evidence for its clinical application:
Clinical Sample Correlation Analysis:
Renal biopsy tissue and serum samples from confirmed diabetic nephropathy patients are collected. Mitochondrial function markers (e.g., serum 8-OHdG, mitochondrial DNA copy number) and inflammation/fibrosis markers (TNF-α, TGF-β1, α-SMA) levels are measured and their correlation with the degree of renal function impairment (urinary microalbumin, serum creatinine) is analyzed. Changes in these markers in patient serum following SS-31 25mg intervention can also be detected to indirectly verify its therapeutic effects in human patients.
Clinical Intervention Trial Design:
Small-scale prospective randomized, double-blind, placebo-controlled clinical trials are systematically conducted for research verification. Patients diagnosed with early-stage diabetic nephropathy (urinary albumin-to-creatinine ratio 30–300 mg/g) are strictly enrolled and randomly divided into an intervention group (daily subcutaneous injection, with multiple different dose gradients) and a blank placebo group. The whole intervention observation period lasts 12–24 consecutive weeks.
Clinical Effect Evaluation Metrics:
Primary clinical endpoints include dynamic long-term changes in urinary albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR). Secondary research endpoints include obvious fluctuating changes in serum levels of inflammation/fibrosis markers (TNF-α, IL-6, TGF-β1), oxidative stress markers (MDA, SOD), as well as morphological changes in renal cortical thickness and blood flow perfusion detected by color renal ultrasound. The total incidence of various mild and severe adverse reactions is also fully recorded to objectively evaluate overall long-term drug safety.
In summary, through a complete, stepwise and progressive multi-dimensional research system that strictly follows the rigorous logical research route of "cellular-level in vitro experiments verifying direct mitochondrial protective effects at the micro level → standardized genetically modified and induced animal disease models replicating complete systemic renal and metabolic pathological lesions → in-depth molecular mechanism analysis identifying core therapeutic action targets and related signaling pathways → prospective human clinical trials exploring practical translational medical value for real-world disease treatment".
The multi-target anti-oxidative and anti-fibrotic protective effects of SS-31 25mg in progressive renal injury and various accompanying metabolic diseases can be comprehensively, systematically and rigorously confirmed from multiple mutually supportive research dimensions. The diversified experimental detection methodologies constructed at each independent research level mutually corroborate, cross-validate and complement one another, effectively guaranteeing outstanding scientific validity, experimental repeatability and long-term result reliability of all acquired research detection outcomes.
references
The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin, 2013
Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet, 2017
SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease, 2022
FAQ
- What are the ingredients in elamipretide?
Each 0.5 mL dose of FORZINITY contains 40 mg of elamipretide (equivalent to 46.8 mg elamipretide hydrochloride), 10 mg benzyl alcohol as a preservative, and 2.07 mg monobasic sodium phosphate (as monohydrate).
- What is elamipretide used for?
Elamipretide injection is used to improve muscle strength in patients with Barth syndrome (rare inherited disorder in males that result in dysfunction in a lipid necessary for energy production that results in damage to heart, muscles and immune system).
- What are the benefits of elamipretide?
These encouraging experimental results strongly suggest that the mitochondrial-targeted peptide Elamipretide possesses prominent biological ability to stabilize damaged mitochondrial structures and restore the normal physiological level of cardiolipin within cardiomyocytes, thereby effectively boosting overall cardiac muscle contractile performance and boosting efficient intracellular energy production under pathological heart failure conditions, while further blocking the pathological cascade to prevent consequential irreversible cardiac hypertrophy and interstitial myocardial fibrosis in failing hearts.
Hot Tags: ss-31 25mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, GLP 1 Peptide CAS 87805 34 3, Melanotan ii powder, Selank Peptide CAS 129954 34 3, Tesamorelin CAS 218949 48 5, Melanotan 2 Powder, Epitalon Powder CAS 307297 39 8